Evidence map›Paper›PMID 26936306›Full record

ArticleJournal of diabetes and its complications

Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study.

Petter Bjornstad, David M Maahs, Lindsey M Duca, Laura Pyle, Marian Rewers, Richard J Johnson, Janet K Snell-Bergeon

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04133922. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawn

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
Open the trial in the graph
NCT05478707 phase2recruiting

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.Advances in chronic kidney disease · 2021 · on this map
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Lipid mediators of insulin signaling in diabetic kidney disease.American journal of physiology. Renal physiology · 2019
    Review
  18. Establishing a Link between Endothelial Cell Metabolism and Vascular Behaviour in a Type 1 Diabetes Mouse Model.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Petter BjornstadDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO. Electronic address: Petter.Bjornstad@childrenscolorado.org.
David M MaahsDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO; Department of Nephrology, University of Colorado Denver, Aurora, CO.
Lindsey M DucaBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO; Colorado School of Public Health, University of Colorado Denver, Aurora, CO.
Laura PyleDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO.
Marian RewersDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO.
Richard J JohnsonDepartment of Nephrology, University of Colorado Denver, Aurora, CO.
Janet K Snell-BergeonDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO.
University of Colorado Denver · USChildren's Hospital Colorado · USColorado School of Public Health · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KRUGMAN, RICHARD D. · 1985 to 2008
$52.6M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Paul S. Maclean · 1995 to 2026
$32.6M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Determinants of Accelerated CVD in Type 1 DiabetesR01HL079611 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 2004 to 2007
$2.3M
NCRR NIH HHS M01 RR000051NCRR NIH HHS NIH-M01-RR00051NHLBI NIH HHS HL113029NHLBI NIH HHS HL79611NHLBI NIH HHS R01 HL061753NHLBI NIH HHS R01 HL079611NHLBI NIH HHS R01 HL113029NHLBI NIH HHS R01 HL61753NIDDK NIH HHS P30 DK057516NIDDK NIH HHS P30 DK57516
6 · The paper itself

Abstract

objectiveReduced insulin sensitivity (IS) is well documented in type 1 diabetes (T1D) and may contribute to vascular complications. We examined the association of estimated IS (eIS) with incident macro- and microvascular complications in adults with T1D in the prospective CACTI study.

methodsParticipants (N=652) were 19-56 years old at baseline and re-examined 6.2±0.6years later. Urinary albumin excretion was measured, and categorized as microalbuminuria or greater. Diabetic retinopathy (DR) was based on self-reported history, proliferative DR (PDR) as history of laser eye therapy and coronary artery calcium (CAC) was measured using electron-beam CT. Progression of CAC was defined as a change in the square root transformed CAC volume score of ≥2.5. IS was estimated (eIS) by an equation derived from clamp studies. Predictors of each complication were examined using stepwise logistic regression and subjects with complications at baseline excluded. Age, T1D duration, sex, HbA1c, SBP, LDL-C, and eIS were considered for inclusion.

resultsGreater eIS at baseline predicted lower odds of developing albuminuria (OR: 0.67, 95% CI 0.51-0.88), DR (OR 0.79, 0.64-0.97), PDR (OR: 0.76, 0.57-0.99) and CACp (OR: 0.71, 0.60-0.85) in multivariable models.

conclusionsGreater eIS conferred protection from the development of vascular complications over 6-years in T1D.

Indexed as

Insulin ResistanceAdultAlbuminuriaCohort StudiesColoradoCoronary Artery DiseaseDiabetes Mellitus, Type 1Diabetic AngiopathiesDiabetic NephropathiesDiabetic RetinopathyDisease ProgressionFemaleHumansIncidenceMaleMiddle AgedInsulin resistanceInsulin sensitivityMacrovascular complicationsMicrovascular complicationsType 1 diabetes

Identifiers

PMID26936306
PMCPMC4834265
OpenAlexW2256255858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.